Researchers have successfully used monoclonal antibodies to protect animal models from Candida infections for the first time, demonstrating their potential for treating this fungal disease.
Collaborative research efforts with scientists from Janssen, the Scripps Research Institute, the University of Hong Kong, the University of Pennsylvania and more has led to success in creating a promising novel long-lasting llama-derived antibody therapy for influenza.
A pioneering treatment, an antibody termed PRN100, is to be given to a patient with sporadic Creutzfeldt-Jakob disease for the first time.
A recent study carried out by researchers from the University of Zurich and University Hospital Zurich has discovered that the production of broad acting antibodies is dependent on the genome of the virus.
Small-molecule compounds designed to tag the cell surface of Gram-negative bacteria and trigger an immunological response have shown promise.
Two genetically-modified broadly-neutralizing antibodies have been demonstrated to elicit long-term protection against an HIV-like virus in rhesus macaques, with a Phase I clinical trial now underway.
A new study has revealed that serum IgA antibodies deliver a protective barrier against polymicrobial sepsis in mice, providing us with a further understanding of its role in host protection.
Learn more about the top news stories of the week in our round-up, including new guidance for drug-resistant infections and a Phase I trials for a MERS treatment.
In this World AIDS Day interview we speak to Richard Koup, who was recently an author on a study reporting a trispecific antibody able to target 99% of HIV strains.
Researchers have designed potent peptide fusion inhibitors that can neutralize a broad range of influenza viruses and could present a promising avenue for future therapeutics.